7th Annual Partnership Opportunities in Drug Delivery (PODD)

7th Annual Partnership Opportunities in Drug Delivery (PODD) is organized by The Conference Forum and would be held during Oct 19 - 20, 2017 at Boston Marriott Copley Place, Boston, Massachusetts, United States of America.

The target audience for this medical event for Business Development, External Licensing, Technology Licensing, Portfolio Management, Research & Technology Development, Pharmaceutical Formulation/Sciences, Licensing, Marketing, Formulation Sciences, Technology Development, Commercial Development.

Conference Objectives :
• To present a strategic level program for pharma and biotech business development professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities to improve therapies and extend the life cycle of a drug.
• To provide drug delivery and specialty pharmas with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.
• To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones.

Choose from 3 tracks (6 sessions) covering a broad range of enabling delivery technologies:

Track 1A :
Injectable Technologies, chaired by Matthew Burke, PhD, Head of Drug Delivery, GSK
Track 2A :
Oral Delivery Technologies, chaired by René Holm, PhD, Head and Scientific Director, Drug Product Development, Liquids and Parenterals, Janssen
Track 3A :
Device Technologies, chaired by Mathias Romacker, Senior Director, Device Strategy, Pfizer

Track 1B :
Injectable Technologies, chaired by Ulrich Bruggemann, Head Academics and Innovation, Global Medical Devices Development, Sanofi US
Track 2B :
Non-Injectable Technologies: Transdermal and Transmucosal, chaired by Robert Saklatvala, PhD, Director, Discovery Pharmaceutical Sciences, Merck
Track 3B :
Device Technologies, chaired by Justin Wright, PhD, VP, Drug Delivery Innovation, DDRandD Technology, Eli Lilly and Co

Additional details will be posted as soon as they are available.